ARTICLE | Product Development
Baby steps beyond beta amyloid
What Alzheimer’s targets beyond amyloid the biopharma industry is pursuing
March 23, 2019 4:15 AM UTC
Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease.
The failure of aducanumab won’t be the final nail in the coffin of the β amyloid hypothesis, but it certainly sends a clarion call for investment in other mechanisms. The good news is that compounds against newer mechanisms are trickling into the clinic, and more lie behind them in preclinical studies. ...
BCIQ Company Profiles